Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Cedric Bogaert"'
Autor:
Lien Lybaert, Kris Thielemans, Steven A. Feldman, Sjoerd H. van der Burg, Cedric Bogaert, Patrick A. Ott
Publikováno v:
Trends in Cancer. 9:503-519
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0acc7b9d7481d6b569d6194da9174a70
https://doi.org/10.1016/j.trecan.2023.02.004
https://doi.org/10.1016/j.trecan.2023.02.004
The identification of immunogenic peptides that will elicit a CD8+ T cell-specific immune response is a critical step for various immunotherapeutic strategies such as cancer vaccines. Significant research effort has been directed towards predicting w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48cab808d032aca454ce6eb981f08c65
https://doi.org/10.1101/2022.06.03.494687
https://doi.org/10.1101/2022.06.03.494687
Personalised immunotherapy aims to (re-)activate the immune system of a given patient against its tumour. It relies extensively on the ability of tumour-derived neoantigens to trigger a T-cell immune reaction able to recognise and kill the tumour cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3cf5d94f2e1516eb4d6fcd95c47d6cda
https://doi.org/10.1101/2022.05.13.491845
https://doi.org/10.1101/2022.05.13.491845
Autor:
Wout de Mey, Phaedra De Schrijver, Dorien Autaers, Lena Pfitzer, Bruno Fant, Hanne Locy, Arthur Esprit, Lien Lybaert, Cedric Bogaert, Magali Verdonck, Kris Thielemans, Karine Breckpot, Lorenzo Franceschini
Publikováno v:
Molecular therapy. Nucleic acids. 29
A flexible, affordable, and rapid vaccine platform is necessary to unlock the potential of personalized cancer vaccines in order to achieve full clinical efficiency. mRNA cancer vaccine manufacture relies on the rigid sequence design of multiepitope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b286c02953c326eea9f92a34cb7883a
https://pubmed.ncbi.nlm.nih.gov/36159589
https://pubmed.ncbi.nlm.nih.gov/36159589
Publikováno v:
Molecular Cancer Therapeutics. 20:CC01-02
Currently, most neoantigen pipelines often focus on the detection of neoantigens derived from mutations in the coding regions of the genome. However, in some cancer indications, the number of mutations detectable in tumours can be very low (low tumou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1671159f97e1787cd5b305adb2a75146
https://doi.org/10.1158/1535-7163.targ-21-cc01-02
https://doi.org/10.1158/1535-7163.targ-21-cc01-02
Publikováno v:
Molecular Cancer Therapeutics. 20:P006-P006
Personalised immunotherapy approaches rely on the ability of tumour-derived neoantigens to elicit a T-cell immune reaction able to recognise and kill the tumour cells expressing them. Clinical attempts to leverage the power of neoantigens have howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff9a997d02d07f6cac259942d1bec468
https://doi.org/10.1158/1535-7163.targ-21-p006
https://doi.org/10.1158/1535-7163.targ-21-p006